Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs TeraWulf Inc — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while TeraWulf Inc trades at $11.15 (market cap $6.59B). The key difference: Spyre Therapeutics Inc. Common Stock and TeraWulf Inc are close in size by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and TeraWulf Inc for 18 Days on average.
| SYRE | WULF | |
|---|---|---|
Market Cap | $7.52B | $6.59B |
Volume | 1,441,031 | 33,904,053 |
Sector | Health | Financials |
52-Week High | $108.92 | $28.98 |
52-Week Low | $22.18 | $10.99 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $6.52B | $9.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
WULF trades at $13.21, down 1.2% on the day, with a bearish technical signal from moving averages. The company reported a net loss of -$661.42M in 2025, with a negative net income margin of -1,179.94%, though it maintains a high gross profit margin of 69.26%. Recent news highlights its pivot to AI data centers, with shares experiencing volatility amid sector-wide momentum.
Analyst consensus is strongly bullish with a $34.92 price target, but high valuation ratios and persistent losses pose significant risks. Investment appeal hinges on successful execution of the AI infrastructure strategy amid substantial financial leverage and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
